GLASGOW, Scotland and BRISBANE, Calif. -- InterMune, Inc. has announced that in vitro studies of its novel antibiotic, oritavancin, demonstrate its potent activity against European isolates of susceptible and resistant strains of Staphylococcus, Streptococcus and Enterococcus. Researchers discussed the data from these studies in an oral presentation and two poster sessions at the European Congress of Clinical Microbiology and Infectious Disease (ECCMID).
Oritavancin, a second-generation glycopeptide antibiotic, is currently being tested in multiple clinical trials, including a multi-center, global Phase III study of more than 1,250 patients with complicated skin and skin-structure infections (CSSIs).
"These findings extend our knowledge of the potent in vitro activity of oritavancin against important and common gram-positive bacteria linked to CSSIs, beyond U.S. to European isolates, demonstrating oritavancin's similarly powerful activity against these organisms," said Steven Porter, MD, PhD, vice president of clinical research, InterMune. "Oritavancin demonstrated potent activity against all organisms tested. In particular, it was more bactericidal (i.e., it kills the bacteria) against enterococci than any other agent tested."
The promising in vitro potency of oritavancin has already been confirmed in a large-scale clinical trial. Data reported last year from a Phase III clinical study of 517 patients with CSSIs demonstrated that oritavancin intravenous therapy can reduce treatment times by one-half of the current standard of care -- intravenous therapy with vancomycin followed by oral therapy with cephalexin. InterMune completed enrollment of a second Phase III clinical trial of oritavancin and expects to report data later this year that will keep the company on track to file an NDA in the first half of 2004.
Staphylococcal infections, including CSSIs, represent a large market and high unmet medical need for new antibiotics. The rates of methicillin-resistant Staphylococcus aureus (MRSA) infections have risen dramatically in Europe. Approximately 30 percent to 40 percent of isolates of Staphylococcus aureus in some European countries are MRSA strains.
"These in vitro study results demonstrating oritavancin's bactericidal activity against gram-positive bacteria are especially compelling given the rising incidence of staphylococcal infections and increasing rates of MRSA infections in Europe," said Dr. Porter. "The potency of oritavancin suggests that it may become an important antibiotic addressing the challenge of antimicrobial resistance in staphylococcal, enterococcal and streptococcal infections in the hospital setting worldwide."
Oritavancin and comparator antibiotics were tested against susceptible and resistant strains of staphylococcus, streptococcus and enterococcus collected from patient specimens in 15 countries in Europe during the years 2000-2001. Broth microdilution methods were utilized and minimum inhibitory concentrations (MICs) for comparator agents were interpreted using the National Committee for Clinical Laboratory Standard's breakpoints published in 2002.
Results discussed in the oral presentation highlight oritavancin's consistent in vitro activity, compared to the other antibiotics tested, against susceptible and resistant isolates of Streptococcus pneumoniae collected from clinical samples of patients in 15 European countries. By minimum inhibitory concentrations, oritavancin was shown to be 32-fold more active than vancomycin and other comparator drugs evaluated. In addition, oritavancin showed consistent, potent activity against all strains of Streptococcus pneumoniae tested, regardless of resistance to other antimicrobial agents.
Data from several poster presentations demonstrated the consistent activity of oritavancin in vitro against susceptible and resistant strains of Staphylococcus aureus and coagulase-negative staphylococci (CNS), including multiple drug-resistant isolates. The activity of oritavancin, vancomycin, oxacillin, and comparator antibiotics were tested against susceptible and resistant isolates of staphylococci, including 697 isolates of Staphylococcus aureus and 265 strains of coagulase-negative staphylococci (CNS). Oritavancin showed consistent activity against susceptible and resistant strains of Staphylococcus aureus and CNS, including isolates that were resistant to five classes of antimicrobial agents.
A second poster presented highlighted the consistent activity of oritavancin in vitro against susceptible and resistant strains of Enterococcus (i.e., E. faecium (EM), E. faecalis (EF), and non-EM, non-EF enterococcal strains), including multiple-drug resistant isolates. Oritavancin and comparator antibiotics were tested against susceptible and resistant isolates of Enterococcus strains including 306 strains of E. faecium (EM), 388 strains of E. faecalis (EF), and 135 non-EM, non-EF enterococcal strains. Oritavancin was the most bactericidal agent tested and showed consistent activity against susceptible and resistant strains of EM and EF, including isolates resistant to multiple antibiotics.
InterMune is a commercially driven biopharmaceutical company focused on the marketing, development and applied research of life-saving therapies for pulmonary, infectious and hepatic diseases.
Source: InterMune, Inc.
Happy Hand Hygiene Day! Rethinking Glove Use for Safer, Cleaner, and More Ethical Health Care
May 5th 2025Despite their protective role, gloves are often misused in health care settings—undermining hand hygiene, risking patient safety, and worsening environmental impact. Alexandra Peters, PhD, points out that this misuse deserves urgent attention, especially today, World Hand Hygiene Day.
From the Derby to the Decontam Room: Leadership Lessons for Sterile Processing
April 27th 2025Elizabeth (Betty) Casey, MSN, RN, CNOR, CRCST, CHL, is the SVP of Operations and Chief Nursing Officer at Surgical Solutions in Overland, Kansas. This SPD leader reframes preparation, unpredictability, and teamwork by comparing surgical services to the Kentucky Derby to reenergize sterile processing professionals and inspire systemic change.
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.
The Rise of Disposable Products in Health Care Cleaning and Linens
April 25th 2025Health care-associated infections are driving a shift toward disposable microfiber cloths, mop pads, and curtains—offering infection prevention, regulatory compliance, and operational efficiency in one-time-use solutions.
Phage Therapy’s Future: Tackling Antimicrobial Resistance With Precision Viruses
April 24th 2025Bacteriophage therapy presents a promising alternative to antibiotics, especially as antimicrobial resistance continues to increase. Dr. Ran Nir-Paz discusses its potential, challenges, and future applications in this technology.